Donor and recipient sex in allogeneic stem cell transplantation: What really matters

Haematologica

Volumn 101, Issue 10, 2016, Pages 1260-1266

  Kim, Haesook T ^a   Zhang, Mei Jie ^b   Woolfrey, Ann E ^c   Martin, Andrew St ^b   Chen, Junfang ^b   Saber, Wael ^b   Perales, Miguel Angel ^d   Armand, Philippe ^a   Eapen, Mary ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID; MYELOABLATIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECIPIENT; RELAPSE; SEX; SEX DIFFERENCE; TREATMENT OUTCOME; ADOLESCENT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; DISEASE FREE SURVIVAL; GRAFT VS HOST DISEASE; MIDDLE AGED; RECURRENT DISEASE; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SEX FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84989332191     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.147645     Document Type: Article

References (24)

1. Gratwohl A, Hermans J, Niederwieser D, van Biezen A, van Houwelingen HC, Apperley J. Female donors influence trans-plant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. Hematol J. 2001;2(6):363-370.
2. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2004;103(1):347-352.
3. Gahrton G, Iacobelli S, Apperley J, et al. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant. 2005;35(6):609-617.
4. Gallardo D, Pérez-García A, de la Cámara R, et al. Clinical outcome after sex-mismatched allogeneic stem cell transplantation from human lymphocyte antigenidentical sibling donors: influence of stem cell source. Leukemia. 2006;20(8):1461-1464.
5. Loren AW, Bunin GR, Boudreau C, et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(7):758-769.
6. Gahrton G. Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation. Best Pract Res Clin Haematol. 2007;20(2):219-229.
7. Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214-3219.
8. Olsson RF, Logan BR, Chaudhury S, et al. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. Leukemia. 2015;29(8):1754-1762.
9. Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(2):266-274.
10. Goulmy E, Termijtelen A, Bradley BA, van Rood JJ. Alloimmunity to human H-Y. Lancet. 1976;2(7996):1206.
11. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105(7):2973-2978.
12. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998; 352(9134): 1087-1092.
13. Gratwohl A, Stern M, Apperley J, et al. The EBMT risk score predicts outcome after allogeneic HSCT in all haematological disease categories and is independent of stem cell source or conditioning intensity. Bone Marrow Transplant. 2008;41:S3.
14. Terwey TH, Hemmati PG, Martus P, et al. A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia. Haematologica. 2010;95(5):810-818.
15. Gratwohl A, Stern M, Brand R, et al. European Group for Blood and Marrow Transplantation and the European Leukemia Net. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115(20):4715-4726.
16. Gratwohl A. The EBMT score. Bone Marrow Transplant. 2012;47(6):749-756.
17. Armand P, Gibson CJ, Cutler C, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120(4):905-913.
18. Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664-3671.
19. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1140-1154.
20. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of competing risk. J Am Stat Assoc. 1999;94:496-509.
21. Zhou B, Latouche A, Rocha V, Fine J. Competing risks regression for stratified data. Biometrics. 2011;67(2):661-670.
22. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipeint HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4567-4583.
23. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919.
24. Kollman C, Spellman SR, Zhang MJ, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016; 127(2):260-267.